Showing results (21-30 of 259) with videos related to

Sort By:
Pageof 26
Blood|May 24, 2015
How I treat Waldenström macroglobulinemiaSteven P Treon
Blood Advances|October 21, 2025
Familial Clusters and Clinical Features, Complications, and Outcomes in 1000 Patients with Waldenström MacroglobulinemiaAndres Ramirez-Gamero, Nickolas Tsakmaklis, Zachary R Hunter, et al.
Clinical Lymphoma & Myeloma|April 14, 2009
Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemiaLeukothea Ioakimidis, Christopher J Patterson, Zachary R Hunter, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 23, 2012
Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemiaSteven P Treon, Christina Tripsas, Christina Hanzis, et al.
Clinical Lymphoma|March 30, 2005
CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemiaZachary R Hunter, Andrew R Branagan, Robert Manning, et al.
American Journal of Hematology|December 28, 2017
Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM reboundJoshua N Gustine, Kirsten Meid, Toni Dubeau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2018
Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström MacroglobulinemiaJorge J Castillo, Kirsten Meid, Joshua N Gustine, et al.
British Journal of Haematology|May 10, 2017
Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemiaJoshua N Gustine, Kirsten Meid, Toni Dubeau, et al.
British Journal of Haematology|February 23, 2018
Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemiaJorge J Castillo, Joshua N Gustine, Kirsten Meid, et al.
Pageof 26